— Mr. Tohru Satoh, President and CEO of SONIRE Therapeutics

New Investors: NISSAY CAPITAL, Japan Growth Capital Investment Corp., Daiwa Corporate Investment, Resona Capital, Carbon Ventures, QR Investment, and JA MITSUI LEASING

Existing Shareholders: Fast Track Initiative (FTI), SBI Investment, Mitsubishi UFJ Capital, FFG Venture Business Partners, and Higin Capital

About SONIRE Therapeutics:

SONIRE was established in February 2020 to develop the next-generation High-Intensity Focused Ultrasound (HIFU) system using the technology and clinical know-how has been built by Tokyo Women’s Medical University, Tohoku University and Tokyo Medical University over the past years. HIFU therapy is expected as a new cancer treatment because it is non-invasive with no risk of radiation, so patients can receive the treatment repeatedly. SONIRE has developed the HIFU therapy system as a new treatment modality targeting intractable cancers such as pancreatic cancer. Visit our homepage here: https://www.sonire-therapeutics.com/en/


About Fast Track Initiative:

Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm, focusing its investments on grow seed and early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including diagnostics, digital health, healthcare services, and more. The company provides full, hands-on operational support to its 30+ portfolio companies through business and R&D strategy, investor syndication, and more, including access to their exclusive network of leading industry professionals in Japan. Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/. For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com

Back to HCB News

Ultrasound Homepage